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Abstract
The trophoblast, i.e. the peripheral part of the human conceptus, exerts a crucial role in
implantation and placentation. Both processes properly occur as a consequence of an intimate
dialogue between fetal and maternal tissues, fulfilled by membrane ligands and receptors, as well as
by hormone and local factor release. During blastocyst implantation, generation of distinct
trophoblast cell types begins, namely the villous and the extravillous trophoblast, the former of
which is devoted to fetal-maternal exchanges and the latter binds the placental body to the uterine
wall. Physiological placentation is characterized by the invasion of the uterine spiral arteries by
extravillous trophoblast cells arising from anchoring villi. Due to this invasion, the arterial structure
is replaced by amorphous fibrinoid material and endovascular trophoblastic cells. This
transformation establishes a low-resistance, high-capacity perfusion system from the radial arteries
to the intervillous space, in which the villous tree is embedded. The physiology of pregnancy
depends upon the orderly progress of structural and functional changes of villous and extravillous
trophoblast, whereas a derangement of such processes can lead to different types of complications
of varying degrees of gravity, including possible pregnancy loss and maternal life-threatening
diseases. In this review we describe the mechanisms which regulate trophoblast differentiation,
proliferation, migration and invasiveness, and the alterations in these mechanisms which lead to
pathological conditions. Furthermore, based on the growing evidence that proper inflammatory
changes and oxidative balance are needed for successful gestation, we explain the mechanisms by
which agents able to influence such processes may be useful in the prevention and treatment of
pregnancy disorders.
Introduction
Trophoblast is an embryonic tissue which exerts a crucial
role during implantation and placentation. Both proc-
esses can only take place through a significant change in
the uterine wall in response to different modulatory mol-
ecules, among which steroid and peptide hormones, as
well as local factors including prostanoids. This transfor-
mation, aimed at creating a favourable environment for
receiving the blastocyst, and permitting embryo-fetal
development, is represented by a complex series of events
termed decidualization. Implantation consists of the blas-
tocyst penetrating the luminal epithelium, crossing the
basal lamina and, finally, embedding itself in the stroma.
During implantation a syncytiotrophoblast (ST) is
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formed, which begins to invade the maternal tissue. After-
wards, vascularization of the trophoblast occurs in order
to establish and maintain a feto-placental vasculature.
Simultaneously, maternal vascular remodeling takes place
so as to generate a utero-placental circulation. For success-
ful placentation to occur, a highly orchestrated control of
vasculogenesis, angiogenesis, and trophoblast functions is
required. This is operated by a large number of heteroge-
neous factors which act by both autocrine and paracrine
mechanisms.
Here we review the control of trophoblast function, high-
lighting the aspects which may improve management of
pregnancy complications.
Decidualization
In order for implantation to occur, endometrium has to
be changed into decidua. This process consists in modify-
ing endometrial stromal cells, uterine glands and vessels,
as well as the population of uterine immune cells. In
humans, unlike other species [1], decidualization is inde-
pendent of the blastocyst's presence in the uterine cavity
and begins in the late secretory phase of the menstrual
cycle. It is evoked by progesterone, as well as by regulatory
agents able to enhance cyclic AMP (cAMP) levels [2,3].
Decidualization continues in pregnancy, and it is thought
to regulate subsequent trophoblast invasion and placenta
formation by altering the expression of regulatory factors
such as metalloproteinases, cytokines, surface integrins,
and major histocompatibility complex molecules. The
trophoblast, in turn, releases paracrine signals which
modulate decidual stromal cell gene expression [4]. These
cells become round and show ultrastructural similarities
with myofibroblasts and epithelial cells [5]. Moreover,
they release several factors including prolactin, relaxin,
renin, insulin-like growth factor binding protein-1
(IGFBP-1) [1,3] and specific extracellular matrix (ECM)
proteins such as laminin and fibronectin [6]. In vitro stud-
ies have demonstrated that this event is correlated with
changes in steroid hormone receptor expression and ster-
oid metabolism, remodeling of the ECM and cytoskele-
ton, altered expression of enzymes, growth factors and
cytokines, and induction of apoptosis modulators and
specific transcription factors [7]. Elongation of the spiral
arteries occurs through an endometrium-specific angio-
genesis, characterized by proliferation of both endothelial
and smooth muscle cells, with preservation of the integral
structure of the vessel. In the uterine wall, several leuko-
cyte types, such as T lymphocytes, a few B lymphocytes,
macrophages, and natural killer (NK) cells, are present.
However, after ovulation, a dramatic increase in NK cells
is observed. Uterine NK cells (uNK) are phenotypically
and functionally different from circulating ones. Indeed,
they have not cytolytic activity [8], and express integrins
which allow their migration and invasion of the decidual-
izing endometrium [6]. It has been suggested that the
unique environment resulting from the transformation of
endometrium to decidua plays a crucial role in uNK cell
specificity acquisition [6,9]. Since decidual NK cells
decrease in number in the second half of pregnancy and
disappear at delivery, it has been hypothesized that their
main role is confined to early pregnancy, when they mod-
ulate implantation and placentation interacting with both
decidual stromal cells and trophoblast [6,9]. Interestingly,
it has been shown that uNK cell recruitment is a hormo-
nally-controlled maternal function and is independent of
the presence of the implanting embryo [10]. NK cell sur-
vival seems to be dependent upon the presence of proges-
terone, whose action, however, is presumably not direct,
but mediated by decidual stromal cells which express hor-
mone receptors [11]. In contrast, it has recently been
shown that glucorticoids are able to decrease the number
of decidual NK cells [12].
Decidualization is also characterized by a decrease in Th1
and an increase in Th2 lymphocytes, an effect which is
evoked by progesterone and cytokines. It has been pro-
posed that Th2 cytokines protect fetus and trophoblasts
inhibiting NK cell cytotoxicity and proliferation, shifting
NK cell cytokine production toward a Th2 phenotype, as
well as suppressing cytotoxic T cells activation [12-14].
Blastocyst implantation
An intimate cross-talk between the embryo and the uterus
is needed for blastocyst implantation [4,15]. This process,
which consists of an interaction between trophoblast cells
and endometrium, can only take place in a restricted
period of time, termed "window of receptivity". It is ini-
tially dependent upon the presence of estrogen and pro-
gesterone, although further morphological and
biochemical changes are evoked within the uterine wall
by signals from the embryo and invading trophoblast. The
"window of receptivity" in humans is presumed to span
days 20–24 of the menstrual cycle [1]. Indeed, out of this
period the epithelium apical surface is covered by a thick
glycocalyx, mainly composed of mucin, and in particular
MUC1, a transmembrane glycoprotein characterized by
an extended extracellular domain which prevents blasto-
cyst attachment [16]. Blastocyst implantation is also
impaired by the large number of desmosomes which exist
along lateral epithelial cell surfaces [17]. In some species
the "window of receptivity" is characterized by down-reg-
ulation of MUC1, but this condition has not been
observed in humans. Some researchers have suggested
that MUC1 may actually promote human blastocyst
attachment to the uterine wall [18], whereas others dem-
onstrated a loss of this mucin at the site of blastocyst inter-
action [19] thanks to uterine proteases, activated by
factors released from the blastocyst itself [16].Reproductive Biology and Endocrinology 2007, 5:6 http://www.rbej.com/content/5/1/6
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Blastocyst attachment to the uterine wall depends upon
the interaction between adhesion molecules such as
selectins, integrins, and trophinins [17], expressed on
both trophoblast cells and uterine epithelium. This inter-
action is mediated, in most cases, by bridging ligands
including, at least in the sheep, osteopontin and galectin-
15, which are released in the uterine cavity by endometrial
glands [20]. Invasion is favoured by the simultaneous
decrease of desmosome density and basal membrane
digestion, finally leading to nidation in the decidual
stroma [17].
A key role in the control of human blastocyst implanta-
tion is exerted by endometrial chemokines and cytokines.
Chemokines are thought to be responsible for the promo-
tion of leukocyte migration to the decidua, where they
cause a sort of inflammatory state, a process which
appears to derive from several sources. First, decidualiza-
tion is characterized by NK cells interaction with the non-
polymorphic HLA class I antigens expressed by invading
trophoblasts [21]. Furthermore, signalling agents secreted
by seminal vesicles and prostate gland interact with epi-
thelial cells in the cervix and uterus, recruiting and activat-
ing macrophages, granulocytes and dendritic cells. They
are provided with immune-regulatory and tissue remodel-
ling roles that improve endometrial receptivity to the
implanting embryo. Tumor growth factor β (TGF-β) and
prostaglandins (PGs) present in seminal fluid contribute
to enhance cytokine production and vascular permeabil-
ity, that appear to be essential for implantation, due to
their effects favouring blastocyst attraction and attach-
ment to the endometrium [13]. Moreover chemokines,
interacting with G protein-coupled receptors, induce a
structural change in integrins which favours adhesion of
the blastocyst to the decidualized endometrium [22]. NO
favours blastocyst implantation in both animals and
humans, modulating PG release, ovarian steroidogenesis,
uterine cell proliferation, glandular secretion and blood
flow, as well as mediating sex steroid and growth factor
actions [15]. Since normal pregnancy is a physiological
process, in our opinion it should not be defined as a 'con-
trolled state of inflammation' [23]. However, at an early
stage at the implantation site, as well as later systemically,
it is regulated by the same cytokines whose derangement
can trigger the inflammatory pathway, leading to various
types of early and late gestational diseases. Under such
profile, the above mentioned 'Th1/Th2' shift hypothesis,
that dominated reproductive immunology for many
years, should be more simply interpreted as the expres-
sion of the modulation of the cytokines that regulate the
vascular processes of placentation, rather than a specific
mechanism to avoid fetal T-cell rejection.
Trophoblast differentiation and function
The formation of floating and anchoring villi begins
immediately after nidation. Three stages are recognized in
the development of the villi, namely primary, secondary
and tertiary villi, the last being characterized by a de-novo
formation of capillaries from mesenchymal precursors
and thus devoted to feto-maternal exchanges. Villous tree
expansion occurs throughtout pregnancy [24].
The specialized villous cell types, i.e. ST and extravillous
trophoblast (EVT) cells, originate from cytotrophoblast
(CT) stem cells. During blastocyst implantation, CT cells
fuse to form an external layer of non-proliferative multi-
nucleated ST which then grows thanks to the steady incor-
poration of new CT cells. ST exerts a crucial role in feto-
maternal exchanges and possesses endocrine activity,
releasing hormones involved in the homeostasis of preg-
nancy such as chorionic gonadotrophin (CG) and placen-
tal lactogen (PL). Around day 14 after implantation, CT
cells break through the ST layer giving rise to EVT cells,
which begin to invade the uterine stroma as trophoblastic
cell columns. From the tips of the columns, a subpopula-
tion of these motile and invasive cells moves laterally, to
form the trophoblastic shell, and longitudinally to invade
deeply the decidua and the deeper portion of the myo-
metrium, where these cells evoke profound changes
within the uterine vessels [25].
Factors involved in the control of CT 
differentiation
Differentiation of CT to ST or EVT cells is precisely con-
trolled by different agents such as transcription factors,
specific genes, hormones, growth factors, cytokines and
O2 levels. The glial cell missing factor 1 (GCM1), together
with the AP-2 and Sp transcription factor families, stimu-
late syncytial fusion, whereas Hash-2 inhibits this process
by reducing CYP19/aromatase gene transcription [26].
Hash-2 and Id-2 maintain CT proliferation, and their
downregulation is observed in differentiated cells [27,28].
The expression of some of the above mentioned transcrip-
tion factors is influenced by O2 levels and cAMP.
A relatively low oxygen environment characterizes blasto-
cyst implantation, placentation and early embryonic
development up to the 10th week of gestation [29].
Accordingly, in the first trimester, the villous trophoblas-
tic layer is twice the thickness it becomes in the second.
Moreover, the intervillous circulation is established
peripherically at around the 9th week, and it enlarges to
encompass the whole placenta only after the 12th week.
This could be due to the presence of trophoblast cell plugs
which occlude the tips of the uteroplacental arteries [30],
or to incomplete spiral artery remodeling [31]. Low O2
levels stimulate CT proliferation and inhibit EVT and ST
differentiation. Hypoxia acts by modifying gene expres-Reproductive Biology and Endocrinology 2007, 5:6 http://www.rbej.com/content/5/1/6
Page 4 of 14
(page number not for citation purposes)
sion or mRNA stability [32]. For instance it stimulates the
expression of both the hypoxia inducible factor-1 (HIF-1),
which maintains CT proliferation, and Hash-2, thus pre-
venting differentiation. Moreover it has been reported
that, in first-trimester trophoblast, HIF-1 expression paral-
lels that of TGF-β3, an inhibitor of early trophoblast dif-
ferentiation which impairs its acquisition of the invasive
phenotype [31,33]. In line with this last report, it has been
observed that invading CT downregulates the expression
of both HIF-1 and TGF-β3 genes [33,34]. cAMP also seems
to be involved in trophoblast differentiation and it has
been shown to influence ST formation. It enhances AP-2
and Sp functionality, promotes the expression of the syn-
cytin gene, a highly fusogenic membrane protein local-
ized at the CT-ST interface, and mediates the
syncytialization evoked by CG [35]. Among growth fac-
tors, the vascular endothelial growth factor (VEGF),
whose expression has been demonstrated in decidual
cells, CT and EVT [36-38], stimulates CT differentiation to
both ST and endovascular EVT, and its effect is inhibited
by soluble fms-like tyrosine kinase-1 (sFlt-1), which acts
by binding VEGF [39].
TGF-β, instead, inhibits differentiation along the invasive
pathway helped by endoglin, a component of TGF-β
receptor complex [40], while tumor necrosis factor (TNF)-
α reduces syncytialization [41]. The involvement of
canonical Wingless (Wnt) signaling and of marinobuf-
agenin, the endogenous sodium pump inhibitor, has
recently been reported in the acquirement of the invasive
phenotype [42,43]. An alteration of trophoblast differen-
tiation may result in pregnancy diseases, such as preec-
lampsia. For instance a persistent hypoxia, together with
an increase of HIF-1 and TNF-α as [44] well as a decrease
of syncytin expression [45], induces a decrement of syncy-
tialization and consequently an enhancememnt of tro-
phoblast apoptosis, an event notoriously involved in
preeclampsia pathogenesis. A schematic representation of
the above described control of trophoblast differentiation
is reported in Fig. 1.
Extravillous trophoblast function
EVT cells originating from the trophoblastic shell first
enter the decidua and subsequently the myometrial
stroma [3] as interstitial trophoblast. This encircles and
destroys the smooth muscle cells of spiral artery media
which is replaced by amorphous fibrinoid material. Sub-
sequently, EVT expressing an endothelial phenotype
invade the lumen of the arteries [46] to replace the
endothelium of the vessels (Fig. 2).
Invasion of endometrial vessels by endovascular EVT is
evident from 8 weeks onward, whereas myometrial artery
invasion begins around the 14th week. This process mainly
involves the vessels in the center of the placental bed, but
also to a lesser extent the peripheral vasculature [47]. The
expression of both angiopoietins and their receptor (Tie-
2) has been observed during early placentation, suggest-
ing an involvement of these regulatory agents in vascular
remodeling. Moreover, the demonstration that Tie-2 is
expressed on trophoblast suggests that angiopoietins may
regulate its functions. For instance, it has been demon-
strated that angiopoietins stimulate proliferation and
migration of cultured cytotrophoblast and EVT cells,
respectively [36]. Since the guinea pig interstitial trophob-
last expresses NO synthases [48], a role for NO in dilating
and remodeling uterine vessels has been hypothesized.
However, human invasive trophoblast does not express
NO synthesizing enzymes [49], and therefore it should
not be able to release this vasoactive molecule. Another
putative vasodilator is carbon monoxide, produced by
hemoxygenase, whose expression has been demonstrated
in all EVT cells [50]. Furthermore, molecules able to inter-
act with each other have been identified in both NK and
EVT cells [9]. In EVT cells MHC class I molecules are
expressed, in particular HLA-C, E and G that are all good
ligands for several members of the killer immunoglobulin
receptor (KIR) family, present on NK cells. Such interac-
tion modifies the NK cell cytokine repertoire and regulates
adhesion molecules as well as matrix metalloproteinase
(MMP) functionality [51]. Interstitial EVT cells move to
the inner myometrium, where they fuse to become pla-
cental bed giant cells (GC) [52]. Since these multinuclear
cells lose their ability to migrate and invade, their forma-
tion is likely to represent a mechanism which prevents
deeper penetration into the uterine wall.
Invading EVT cells up-regulate the expression of proteins
which favour uterine wall invasion, including MMPs,
α5β1 and α1β1 integrins, VE-cadherin, and the trophob-
last specific HLA class 1 molecule (HLA-G) which proba-
bly exerts a role in preventing fetal rejection. Conversely,
these cells down-regulate the expression of adhesion mol-
ecules, such as α6β4 integrin or E-cadherin, unqualified
for the invasion process, or of regulatory factors which
inhibit cell invasiveness [53].
In addition to CT differentiation, O2 levels also influence
EVT cell function. An inhibitory effect of hypoxia on EVT
cell invasiveness has been reported [31,33,54], which is
thought to be due to a modification of the integrin expres-
sion pattern which is, in turn, influenced by components
of the ECM [54]. However, under different experimental
conditions, an enhancement of trophoblast cell line inva-
siveness has also been observed [55]. This effect has been
related to an enhanced expression of urokinase-type plas-
minogen activator (uPAR), an event which then results in
the activation of plasmin and latent MMPs [55]. Accord-
ing to Genbacev et al [31] hypoxia does not inhibitReproductive Biology and Endocrinology 2007, 5:6 http://www.rbej.com/content/5/1/6
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cytotrophoblast differentiation/invasion before the 7th
week of gestation.
Modulation of EVT function is a complex phenomenon
which depends on a growing number of factors [13,56],
beside those above described. However, the majority of
available data were obtained from in vitro experiments,
and contrasting responses may derive from different
experimental conditions [57,58]. It is therefore impossi-
ble at present to describe the in vivo picture. Some of the
key regulators of EVT functions are listed in Table 1.
The influence of the oxidative balance on 
trophoblast functions and embryo development
The oxidative balance in the gestational sac, besides influ-
encing CT differentiation and EVT cell function, affects
embryo survival and development. It is known that
hypoxia in embryonic stem cells evokes HIF-1 gene
expression which, in turn, activates multiple genes
involved in both proliferation/differentiation and in cel-
lular adaptive responses to low O2 availability [74].
The hypoxic milieu, in which the conceptus develops in
early pregnancy, may serve to protect fetal tissues and
developmental processes against the deleterious effects of
the reactive oxygen species (ROS), during critical phases
of embryogenesis and organogenesis. This protection is
potentiated by the existence of internal and external anti-
oxidant defense mechanisms. The former mainly com-
prise antioxidant enzymes such as superoxide dismutase,
glutathione peroxidase and gamma-glutamylcysteine syn-
thase. Transcripts encoding for these enzymes have been
demonstrated in the oocyte, embryo and oviduct, and
their expression seems essential to embryo acquisition of
the propensity to develop. External defense mechanisms
are represented by non-enzymatic antioxidants such as
hypotaurine, taurine and ascorbic acid which are found in
follicular and tubal fluids [75]. On the other hand, it has
Schematic representation of cytotrophoblast (CT) differentiation to syncytiotrophoblast (ST) or extravillous trophoblast  (EVT), together with some of the key factors involved in the control of these events Figure 1
Schematic representation of cytotrophoblast (CT) differentiation to syncytiotrophoblast (ST) or extravillous trophoblast 
(EVT), together with some of the key factors involved in the control of these events. The box on the left lists factors stimulat-
ing CT proliferation, thus inhibiting differentiation. Boxes on the right list factors stimulating or inhibiting ST or EVT cell forma-
tion.Reproductive Biology and Endocrinology 2007, 5:6 http://www.rbej.com/content/5/1/6
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been established that human trophoblast cells, exposed to
ROS or other cytotoxicants, overexpress the metal-binding
protein metallothionein, which exerts a protective role by
both direct and indirect mechanisms. In fact this protein
is thought to bind and hence neutralize these toxicants,
simultaneously releasing normally bound zinc, which
possesses cytoprotective actions [76]. A schematic repre-
sentation of defence mechanisms against ROS is reported
in Fig. 3.
O2 tension increases sharply at the end of the first trimes-
ter, when an enhancement of oxidative stress markers as
well as of mRNAs for antioxidant enzymes occurs in tro-
phoblast cells [77]. Such enzyme expression could be
induced by NAD(P)H oxidases [78], stimulated by
hypoxia itself, which leads to intracellular superoxide
anion production. This subsequently upregulates the
expression of antioxidant enzymes, possibly contributing
to modulation of EVT function. Indeed, it has been dem-
onstrated that superoxide evokes the expression of HIF-1
and other genes related to vascular and matrix remode-
ling, as well as to cell apoptosis [78]. On the other hand,
it is believed that a premature and widespread onset of
maternal placental circulation, before the development of
antioxidant defense in the placenta, is correlated to oxida-
tive trophoblast damage and could represent a cause of
early pregnancy loss [30].
The demonstration that physiological concentrations of
ROS exert beneficial effects has led to the formulation of
the "free radical theory of development". According to
this theory, time course and pattern formation in develop-
ing organisms may be influenced by differential O2 sup-
plies and/or gradients in the intracellular redox state [79].
Indeed, it is known that low ROS concentrations stimu-
late cell proliferation as well as gene expression, and it has
been suggested that ROS favourable actions may be
related to their control of the local inflammatory reaction.
Maternal spiral artery remodeling through the combined action of interstitial and endovascular extravillous trophoblast cells Figure 2
Maternal spiral artery remodeling through the combined action of interstitial and endovascular extravillous trophoblast cells.
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Recently, it has been evinced that physiological levels of
ROS induce the expression of several cellular transcrip-
tional factors, through the activation of multiple signal
transduction pathways [80]. In contrast, high ROS levels
are notoriously detrimental for cell survival and func-
tions. In vitro investigations showed that the increased O2
requirement by developing embryos enhances the rate of
ROS production, thus representing a potential teratologi-
cal threat to fetal tissues, as shown in the mouse model
[81]. Moreover, injury caused by oxidative stress may be
responsible for developmental retardation and arrest of
mammalian preimplantation embryos. As for the mecha-
nism responsible for this, it has been hypothesized that
high ROS formation may initiate and propagate an
inflammatory process, resulting in placental tissue apop-
tosis [82].
The role and modulation of the oxidative balance in preg-
nancy have recently been reviewed by Biondi et al [83].
Pathologic pregnancy
Perturbation of trophoblast functions may result in a
range of adverse pregnancy outcomes such as malforma-
tion, fetal growth retardation, spontaneous abortion and
stillbirth. For instance, a limited trophoblast invasion of
maternal vessels has been correlated to both preeclampsia
and fetal growth restriction, whereas an excessive tro-
phoblast invasion is associated with invasive mole, pla-
centa accreta and choriocarcinoma.
However, in spite of the the quantity of literature regard-
ing the physiopathology of trophoblastic functions, the
mechanisms leading to a successful pregnancy are far
from fully understood. A modern approach to the matter
is represented by the attempt to investigate the behaviour
of the regulatory factors which are known to carry a high
risk of spontaneous abortion in pregnancies, such as those
complicated by fetal aneuploidy. Results obtained in this
field demonstrate that chromosomal alterations in the
embryo are correlated with anomalous amniotic and
maternal plasma levels of growth factors and proinflam-
matory cytokines [84,85] which may impair trophoblast
function. This concept is supported by the demonstration
that trisomy 21 is associated with various defects in CT
differentiation represented by down-regulation of adhe-
sion molecules such as integrin α1 and, possibly as a com-
pensatory mechanism, upregulation of MMP-9. These
alterations may be responsible for the increase in CT
apoptosis at the maternal-fetal interface [86].
Preeclampsia, a multifactorial syndrome thought to be
caused by a combination of genetic, environmental,
immunological and nutritional factors affects approxi-
mately 2–3% of all pregnant women and is a major cause
of maternal and fetal morbidity and mortality. It is gener-
ally diagnosed in the third trimester and it is frequently,
though not necessarily, responsible for pregnancy-
induced hypertension and proteinuria. The pathological
basis behind the clinical symptoms is represented by gen-
Table 1: some of the key factors regulating EVT cell functions
Factors Source Effect Ref.
Proliferation Migration Invasiveness
Adhesion molecules Trophoblast ↑↓ ↑↓ 53
Angiopoietins Decidua, trophoblast ↑ 36
Colony Stimulating Factor-1 Placenta, decidua ↑ 59
Decorin Decidua ↓↓↓ 60
Epidermal Growth Factor Decidua, trophoblast ↑↑ 61
Endothelin Placental blood vessels, CT, ST, EVT ↑ 62
Hepatocyte Growth Factor Decidua, trophoblast ↑↑ 63
Insulin-like Growth Factor II Trophoblast ↑↑ 64,65
Insulin-like Growth Factor Binding 
Protein-1
Decidua ↑↑ 64,65
Melanoma Cell Adhesion Molecule Uterine smooth muscle cells ↓ 66
Metalloproteinases Trophoblast ↑ 67
Nodal Placenta ↓ 68
Hypoxia ↑↓ 54,55
Urokinase-type Plasminogen Activator Trophoblast ↑↑ 69
Prostaglandin E2 Decidua, trophoblast ↑ 57
↓↓ 58
8-iso-PGF2α Decidua ↓ 70
Placental Growth Factor Trophoblast ↑ 71
TGF-β Decidua, trophoblast, uNK cells ↓↓↓ 61,64
TNF-α Decidua, uNK cells, decidual macrophages ↓ 72
VEGF Decidua, trophoblast ↑ 73Reproductive Biology and Endocrinology 2007, 5:6 http://www.rbej.com/content/5/1/6
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eralized vasoconstriction, increased vascular reactivity,
parenchymal hypoperfusion, excessive edema, and plate-
let activation triggering the coagulation cascade [87].
In normal pregnancy, as described above, EVT cells trans-
form the spiral arteries into low-resistance vessels. In
preeclampsia, however, spiral artery remodeling is defec-
tive and the utero-placental circulation remains in a state
of high resistance (Fig. 4). It has been hypothesized that
poor placental perfusion per se is an insufficient prerequi-
site for preeclampsia; as a matter of fact, this pathologic
condition appears only when altered placentation occurs
together with maternal constitutional factors [69]. Both
the mother and fetus contribute to preeclampsia, the fetal
contribution being affected by paternal genes. Indeed,
Hiby et al [88] recently indicated the following factors cor-
related to preeclampsia: HLA-C, on fetal trophoblast cells
and KIRs, on maternal decidual NK cells. Both of these
factors are characterized by an extensive polymorphism of
immunological importance in this condition. In particu-
lar they suggest that mothers lacking most or all activating
KIR are at a greatly increased risk of preeclampsia when
the fetus possesses HLA-C belonging to the HLA-C2
group. In preeclampsia the dialogue between EVT and NK
cells necessary for a correct spiral artery remodeling dur-
ing early pregnancy cannot take place.
Several other factors have been implicated in the poor
remodeling of spiral arteries, such as a defect in EVT cell
differentiation toward the invasive phenotype, an increase
in apoptosis, an imbalanced control of migratory and
invasive EVT functions, and the inability of cells to adopt
Antioxidant mechanisms which protect the embryo against ROS excessive formation Figure 3
Antioxidant mechanisms which protect the embryo against ROS excessive formation. Superoxide dismutase (SOD), glutath-
ione peroxidase (GPX) and gamma-glutamylcysteine synthase (GCS) transcripts have been identified in the oocyte, embryo and 
oviduct. The non-enzymatic antioxidants hypotaurine, taurine and ascorbic acid have been found in follicular and tubal fluids. 
Metallothionein is synthesized by trophoblast cells, and acts by neutralizing ROS and releasing the cell survival factor Zn2+.
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an endovascular phenotype [69,89,90]. In contrast, Bro-
sens et al [3] proposed the scarce myometrial artery trans-
formation may be due to a deficient myometrial
decidualization, rather than to defective trophoblast inva-
sion. Nevertheless, it has been reported that in preeclamp-
sia CT cells fail to down-regulate α6β4, to up-regulate
α1β1 integrins and to enhance MMP and HLA-G expres-
sion, whereas they maintain an elevated production of E-
cadherin and of the anti-invasive factor, TGF-β [52].
Moreover, Redline et al [91] demonstrated that this path-
ological condition is associated with an excess of prolifer-
ative immature intermediate trophoblast cells, probably
due to dysregulation of some cytokine and growth factor
secretion. Indeed altered levels of several cytokines, pro-
duced at the maternal-fetal interface and involved in the
physiological control of EVT cell proliferation, differenti-
ation and function, have been found in the blood of
preeclamptic women [87]. It has also been hypothesized
that enhancement of IL-2 production, due to the reduced
placental HLA-G expression, is responsible for the scarce
invasiveness of preeclamptic trophoblast [92], and that
deficiency of IL-10 may contribute to enhanced inflam-
matory responses elicited by TNF-α and interferon-γ
towards the trophoblast [50]. The enhanced pro-inflam-
matory/anti-inflammatory cytokine ratio is mainly due to
the shift to a Th1-predominant state, clearly demonstrated
in preeclampsia, and probably associated to an excessive
production of inflammatory agents, among which IL-12
[14]. Abnormalities in TGF-β3 expression are also associ-
ated with preeclampsia and it has been demonstrated that
down-regulation of this growth factor restores the invasive
capability of preeclamptic trophoblast cells [34]. Caniggia
Spiral artery remodeling in normal and abnormal placentation Figure 4
Spiral artery remodeling in normal and abnormal placentation. During normal placentation, EVT cells invade uterine wall and 
maternal spiral arteries replacing smooth muscle with fibrinoid material and part of vessel endothelium, thus evoking artery dil-
atation. Decidual immune cells, like macrophages and NK cells, facilitate deep invasion of EVT cells up to myometrial portions 
of spiral arteries. A limited EVT cell invasion, in abnormal placentation, impairs the formation of the high-capacity, low-resist-
ance feto-maternal circulation needed for an adequate oxygen and nutrient supply for the growing fetus. For cell type descrip-
tion, see figure 2.
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et al [33] hypothesized that an up-regulation of both TGF-
β3 and HIF-1 expression, secondary to a failure in the
change in O2 tension during early placentation or to a
defect in the ability of trophoblast cells to respond to this
change, could arrest trophoblast differentiation along the
invasive pathway. Alterations in the invasion-regulating
system, uPA/uPAR/PAI, may also contribute to the devel-
opment of preeclampsia since reduced levels of uPA and
increased concentrations of PAI-1 have been reported in
preeclamptic mothers. Such an observation is in line with
the demonstration that most of the MMP-9 secreted by
the preeclamptic trophoblast is in an inactive form, and
that antibodies against uPAR are found in pregnant
women with a history of fetal loss [69].
Placental ischemia, consequent to poor spiral artery
remodeling [87], enhanced Th1/Th2 ratio [93] and pro-
angiogenic/anti-angiogenic factor imbalance [94] may
promote inflammatory changes through the release of Th-
1 cytokines and ROS with consequent endothelial dys-
function, leading to the release of humoral factors respon-
sible for the clinical symptoms of preeclampsia [69].
Several pieces of evidence suggest an involvement of ROS
in endothelial alterations of the syndrome [69,83,95,96].
High decidual levels of oxidative stress markers have been
found in preeclamptic decidua [95], and some of these are
able to inhibit EVT cell invasiveness [96]. Moreover a
reduction in glutathione peroxidase has been demon-
strated in the preeclamptic placenta, probably correlated
with increased in vitro placental production of lipid
hydroperoxides and thromboxane A2 (TXA2), a vasocon-
strictive and pro-aggregatory compound, normally coun-
terregulated by prostacyclin (PGI2). The consequent
TXA2/PGI2 imbalance could contribute to the state of high
resistance of the utero-placental circulation in preeclamp-
sia. Since NO enhances vasodilatatory action of PGI2 and
inhibits TXA2-mediated-vasoconstriction, its reported
decrease in preeclampsia could worsen vascular dysfunc-
tion [97]. An enhancement of placental NAD(P)H oxidase
activity, possibly stimulated by the increased vascular
resistance, has recently been implicated in preeclampsia.
Excessive superoxide production could be detrimental,
both directly and indirectly, through an increase of
cytokine expression [77].
It has been reported that trophoblast cell-derived debris, a
by-product of apoptosis in the outer layers of the develop-
ing and mature placenta, is present in maternal blood dur-
ing normal pregnancy. It increases in the blood of
preeclamptic women, probably due to an exaggerated
apoptosis or even ischaemic necrosis of the oxidatively
stressed placenta. This event could represent a further
pathogenic mechanism of preeclampsia, through the
release of pro-inflammatory cytokines [98].
Therapeutic approaches
In spite of a large amount of research in recent years, the
mechanisms underlying physiological pregnancy and
their changes which trigger pathological conditions are
not completely understood. However, a strong correlation
between the features of the inflammatory response and
the adverse outcomes of pregnancy has recently been
found. Indeed, inflammation is able to subvert the physi-
ological changes that regulate placental perfusion and
myometrial tone. Further investigation into the molecules
involved in physiological and pathological pregnancy
should pave the way to their use, as well as that of their
agonists and antagonists, as therapeutic agents. From this
perspective, control of the maternal inflammatory
response and its influence on vascular and myometrial
functions can be accomplished by administration of pro-
gesterone and glucocorticoids. Indeed, it has already been
established that these hormones influence Th1/Th2 bal-
ance in early pregnancy by inhibiting Th1 response, thus
favouring anti-inflammatory cytokine production
[99,100]. It is also known that, in cases of recurrent preg-
nancy loss, a Th1 milieu which increases peripheral NK
cell number and infiltration of such cells in the
endometrium is formed [12,101]. Furthermore, it has
recently been demonstrated that glucocorticoids at doses
equivalent to those which enhance fetal lung maturity
inhibit pro-inflammatory cytokine production in explants
from normal and preeclamptic placenta, without altering
anti-inflammatory cytokine release [102]. In addition, it
has been observed that, at least in mice, progesterone
action is exerted through an interaction with glucocorti-
coid receptors and that corticosterone is 10–100 times
more effective than progesterone [99]. However, while
progesterone is currently employed as a therapeutic tool
during early gestation, the use of glucocorticoids is gener-
ally still restricted to the prevention of neonatal respira-
tory distress syndrome, necrotizing enterocolitis and
other severe third trimester complications. The reasons for
such a clinical attitude are not clear. They may be due to a
deeper concern about the teratogenic effects of glucocorti-
coids compared with progesterone. Corticosteroid treat-
ment has been found to be ineffective in recurrent
pregnancy loss associated with autoantibodies [103].
However it has been reported that low doses of glucocor-
ticoids are not only harmless but even effective in the pro-
tection of pregnancy in cases of recurrent abortion of
unknown origin [104]. Such efficacy is confirmed daily in
our clinical experience. Moreover, recent reports indicate
a beneficial effect of preconceptual prednisolone treat-
ment on the outcome of pregnancy in women with his-
tory of unexplained recurrent abortion and characterized
by elevated levels of NK cells within the endometrium
before treatment. In all of these cases, NK cells are reduced
upon prednisolone administration [105-107]. Knowing
that uNK recruitment is a hormonally-controlled mater-Reproductive Biology and Endocrinology 2007, 5:6 http://www.rbej.com/content/5/1/6
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nal function [10], and that an increased number of these
cells is associated with recurrent miscarriage, NK cell cyto-
toxicity may well represent part of the mechanism by
which conceptus rejection takes place. This concept
should favour administration of low glucocorticoid doses
with a view to preventing sporadic and recurrent abortion,
a philosophy currently applied in our clinical practice,
which urgently requires extensive investigation. Indeed, it
can be speculated that while progesterone is needed in
order to prepare the endometrium for the earliest phase of
implantation, the subsequent stages of placentation
depend on adequate maternal glucocorticoid production,
aimed at controlling the factors involved in the inflamma-
tory response which occurs naturally in any tissue remod-
eling. Based on the above considerations, the
administration of glucocorticoids in early pregnancy
could be useful to induce the appropriate maternal
cytokine environment. Such a role of corticosteroids in
securing pregnancy from inflammatory wastage is further
enforced by the evidence that mifepristone, a drug
employed to induce medical abortion, is a potent antiglu-
cocorticoid [108].
In light of the recent demonstration that some antibiotics,
such as ampicillin, reduce amniotic PGE2 [109,110] and
IL-6 release both in vitro and in vivo [111], by a mechanism
independent of their antibacterial properties, their use in
the management of the feto-maternal inflammatory state
should also be considered. Based on the detrimental role
of TXA2/PGI2-imbalance in the pathogenesis of preec-
lampsia, a further therapeutic strategy could be repre-
sented by the administration of specific prostanoid
blockers, such as pirmagrel, a strong inhibitor of throm-
boxane production in normal and preeclamptic cytotro-
phoblast [112]. In addition, the clinical benefits of
heparin and aspirin in cases of poor pregnancy outcome,
such as antiphospholipid syndrome, are also recognized.
The use of low doses of these drugs in the management of
early pregnancy dysfunction is justified by their influence
on EVT differentiation [113] and apoptosis [114]. Finally,
considering that inflammation and oxidative stress are
features of preeclampsia, a combination of low-dose aspi-
rin and antioxidants like vitamins C and E has been advo-
cated in management of the syndrome, although the
possible benefit of such a therapy is still awaiting ade-
quate clinical investigation [95].
Concluding remarks
Advances in recent years have demonstrated that preg-
nancy outcome depends upon a profound dialogue
between the decidua and trophoblast. Such a dialogue is
sustained by CT differentiation into ST, as well as EVT, in
order to invade maternal spiral arteries for optimal fetal
oxygenation and nutrition. A pivotal role in this process
has been ascribed to unique uterine wall NK cells, which
are characterized by the ability to produce anti-inflamma-
tory cytokines. It is worth noting that both maternal and
paternal factors are responsible for NK cell acquisition of
this ability, which appears to depend upon a shift of Th1
towards the Th2 phenotype. Indeed, although a weak
inflammatory state is observed during physiological gesta-
tion, an exacerbation of this condition is certainly
involved in the pathological events leading to pregnancy
loss. A delicate balance between free radicals and antioxi-
dants is also essential for normal gestation, since low
doses of radicals are thought to be beneficial for both
embryo development and por-inflammatory cytokine
control, although their potentiated levels may represent a
teratologic threat to fetal tissues and are detrimental for
placenta formation. In light of these conclusion, anti-
inflammatory and antioxidant therapies are currently
evaluated in an attempt to contrast the adverse conditions
which lead to pathological pregnancies. Administration
of glucocorticoids before conception, or during preg-
nancy, to prepare and maintain the proper environment
for implantation, placentation and fetal growth, appears
to represent a new strategy in the battle against pregnancy
loss, needing thorough clinical investigation.
Challenges for future research will be to obtain a complete
picture of the factors which influence the mechanism of
placentation and to identify the very early markers of
pathological pregnancies. Progress in this field could
allow to design new drugs able to easily reach the feto-
maternal unit and suitable for controlling the cytokines
involved in the physiological progression of pregnancy.
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